advanced breast cancer (metastatic)

     

Select
Display
Trial Studied trt Control trt patientstagsNCTROB Result

selective estrogen receptor modulator (SERM)

not classified
NCT02311933 ongoing NCT02311933 ongoing
NCT01327781 ongoing NCT01327781 ongoing
tamoxifen
Viladiu, 1985 -
Kuss, 1997tamoxifen -
De Lena, 1990tamoxifen -
Takatsuka, 1989tamoxifen 20 mg/day40 mg/day -
Ingle, 1986tamoxifenbilateral oophorectomy -
Perry, 1985tamoxifen + CATCAT -
Mouridsen, 1985tamoxifen + CMFCMF -
Spooner, 1991loading dose regimen of tamoxifenconventional dosing -
Gockerman, 1986tamoxifendiethylstilbestrol -
Beex, 2006intermittent tamoxifenIntermittent tamoxifen -
Muss, 1994tamoxifenmedroxyprogesterone -
Castiglione-Gertsch, 1993tamoxifenmedroxyprogesterone acetate -
van, 1986tamoxifenmedroxyprogesterone acetate -
Stuart, 1996tamoxifenmegestrol acetate -
Gill, 1993tamoxifenmegestrol acetate -
Ettinger, 1986tamoxifenmegestrol acetate -
Kellokumpu-Lehtinen, 1987tamoxifennandrolone decanoate -
Beelen, 2014tamoxifenno systemic treatment -
Sawka, 1997tamoxifenovarian ablation -
Willsher, 1996tamoxifenradiotherapy -
Mauriac, 1986alternatingsuccessive -
Buchanan, 1986tamoxifensurgical oophorectomy -
toremifene
Nomura, 1993toremifenetamoxifennegative
Gershanovich, 1997toremifenetamoxifennegative
Milla-Santos, 2001toremifenetamoxifennegative
Hayes, 1995toremifenetamoxifennegative
Stenbygaard, 1993toremifenetamoxifennegative
Pyrhonen, 1997toremifenetamoxifensuggesting

AKT Inhibitors

not classified
MANTA ongoing AZD2014 + FULlulvestrant alone AI failure NCT02216786Exploratory ongoing
BEECH ongoing AZD5363 + wPTXweekly paclitaxelweekly paclitaxelNCT01625286 ongoing

angiogenesis inhibitors

not classified
LEAbevacizumab + endocrine therapyendocrine therapy -
De Jongenzastaurin + fulvestrantFulvestrant -
Dickler (CALGB 40503°, 2015Letrozole plus bevacizumabletrozole -
bevacizumab
RIBBON-I (Robert) on top capecitabine, 2009bevacizumab + capecitabinecapecitabine 1st line suggesting
AVF2119g (Miller) cape, 2005bevacizumab + capecitabinecapecitabine 2nd line Risk of bias suggesting
RIBBON-2 (Brufsky), 2009bevacizumav + CTCT alone 2nd line suggesting
AVADO (Miles) 15mg , 2009bevacizumab + docetaxeldocetaxel 1st line HER-2 negative suggesting
AVADO (Miles) 7.5mg, 2010bevacizumab + docetaxeldocetaxel 1st line HER-2 negative negative
Burstein, 2005bevacizumab + methotrexatemethotrexatenegative
Martin bevacizumab, 2011bevacizumab + paclitaxelpaclitaxel 1st line HER-2 negative negative
E2100 (Miller), 2007bevacizumab + taxanestaxanes 1st line NCT00028990Risk of bias suggesting
RIBBON-I (Robert) on top Tax or anthra, 2009bevacizumab + taxanestaxanes 1st line suggesting
ceritinib
Hyamscediranib + fulvestrantfulvestrantNCT00454805 -
motesanib
Martin (motesanib), 2011motesanib + paclitaxelpaclitaxel 1st line HER-2 negative NCT00356681 -
sorafenib
RESILIENCE, 2013 ongoing sorafenib + capecitabinecapecitabine alone ongoing
Schwartzberg, 2013sorafenib + gemcitabine or capecitabinegemcitabine or capecitabine alone 2nd line HER-2 negative NCT00493636Exploratory suggesting
Gradishar, 2013sorafenib + paclitaxelpaclitaxel alone 1st line HER-2 negative Exploratory negative

Anthracyclines based regimen

not classified
Stewart, 1997CNFCAF -
Smalley, 1983CAFCMFVP -
ANZBC, 1986sequentiallycombination -
Namer, 2001MVFAC/FEC -
French Epirubicin Study , 1988FACFEC -
Italian Study, 1988FACFEC -
EjlertsenFEC x 24 + tamoxifenFEC x 8 + tamoxifen -

aromatase inhibitors

not classified
Goss, 1999vorozolemegestrol acetatesuggesting
Rose, 1986aminoglutethimide + tamoxifentamoxifennegative
aminoglutethimide
Mercer, 1993aminoglutethimidehydrocortisonenegative
Canney, 1988aminoglutethimidemedroxyprogesterone acetatesuggesting
Garcia-Giralt, 1992aminoglutethimidemedroxyprogesterone acetatenegative
Samonis, 1994aminoglutethimidemedroxyprogesterone acetatenegative
Lundgren, 1989aminoglutethimidemegestrol acetatenegative
Russell, 1997aminoglutethimidemegestrol acetatenegative
Alonso-Munoz, 1988aminoglutethimidetamoxifennegative
Gale, 1994aminoglutethimidetamoxifennegative
Ingle, 1986aminoglutethimide + tamoxifentamoxifennegative
Powles, 1984combination of hormone therapiestamoxifennegative
anastrozole
Mauriac, 2003anastrozolefulvestrantnegative
Buzdar a, 1996anastrozolemegestrol acetatenegative
TARGET (Bonneterre), 2001anastrozoletamoxifensuggesting
Milla-Santos, 2003anastrozoletamoxifennegative
exemestane
Chia, 2008exemestanefulvestrantnegative
Kaufmann, 2000exemestanemegestrol acetatenegative
Paridaens, 2003exemestanetamoxifennegative
fadrozole
Bezwoda, 1998fadrozolemegestrol acetatenegative
Buzdar b, 1996fadrozolemegestrol acetatenegative
Buzdar c, 1996fadrozolemegestrol acetatenegative
Thuerlimann, 1996fadrozoletamoxifennegative
Falkson, 1996fadrozoletamoxifennegative
formestane
Kleeberg, 1997formestaneanastrozolenegative
Thuerlimann, 1997formestanemegestrol acetatenegative
Freue, 2000formestanemegestrol acetatesuggesting
Perez Carrion, 1994formestanetamoxifennegative
letrozole
Gershanovich, 1998letrozoleaminoglutethimidenegative
Rose, 2003letrozoleanastrozolenegative
Goss, 2007letrozoleatamestane + toremifenenegative
Tominaga, 2003letrozolefadrozolenegative
Buzdar, 2001letrozolemegestrol acetatesuggesting
Dombernowsky, 1998letrozolemegestrol acetatenegative
Mourisden, 2001letrozoletamoxifennegative

Capecitabine containing-regimen

capecitabine
Oshaughnessy, 2001capecitabineCMF -
Joensuu, 2009capecitabinecontrolNCT00114816 -
Stockler, 2011capecitabinecyclophosphamide, methotrexate, and 5-fluorouracil -
GeparQuattro, 2010capecitabine docetaxeldocetaxelNCT00288002 -
Mavroudis, 2010capecitabinedocetaxel + epirubicin -
Verma, 2005capecitabine + docetaxeldocetaxel alone -
Miles, 2004capecitabine + docetaxeldocetaxel alone -
O'Shaughnessy, 2002capecitabine + docetaxeldocetaxel alone -
Lee, 2008capecitabine + docetaxeldoxorubicin + cyclophosphamide -
Horicapecitabine MPAIV CT -
Talbot, 2002capecitabinepaclitaxel -
Moiseenko, 2000capecitabinepaclitaxel -
Jäger, 2010capecitabinepegylated liposomal doxorubicin -
EORTC 10001 (Pajk), 2008capecitabinevinorelbine -

CDK (cyclin-dependent kinase) inhibitor

abemaciclib
MONARCH 3, 2017Abemaciclib +nsAInsAI 1st line HER-2 negative HR positive postmenopausal NCT02246621Low risk of bias conclusive
palbociclib
PEARL ongoing palbociclib + exemestanecapecitabine HER-2 negative HR positive nsNAI failure NCT02028507Risk of bias ongoing
PALOMA 3, 2015palbociclib + fulvestrantfulvestrant alone2nd line 2nd line HER-2 negative HR positive NCT01942135Low risk of bias conclusive
PALOMA-4 ongoing palbociclib + letrozoleletrozole alone Asian HER-2 negative HR positive postmenopausal NCT02297438Low risk of bias ongoing
PALOMA-2, 2016palbociclib + letrozoleletrozole alonefirst line 1st line HER-2 negative HR positive postmenopausal NCT01740427Low risk of bias conclusive
PALOMA 1/TRIO-18, 2015palbociclib + letrozoleletrozole alone 1st line HER-2 negative HR positive postmenopausal NCT00721409Exploratory suggesting
PENELOPE-B ongoing palbociclibplacebo HR positive NCT01864746Low risk of bias ongoing
ribociclib
MONALEESA-3 ongoing ribociclib (LEE011)+ fulvestrantfulvestrant alone postmenopausal NCT02422615Low risk of bias ongoing
MONALEESA-2, 2016ribociclib (LEE011) + letrozoleletrozole alonefirst line 1st line HER-2 negative HR positive postmenopausal NCT01958021Low risk of bias conclusive
MONALEESA-7 ongoing ribociclib (LEE011) + nsAI/TAM gosnsAI/TAM + gos HER-2 negative HR positive premenopausal NCT02278120Low risk of bias ongoing

combination chemotherapy with platinum salts

cisplatin
Costanza, 1999carboplatin followed by CAFCAFsuggesting
Creagan ET, 1984CAPCFPsuggesting
Cocconi, 1991cisplatin + etoposideCMFsuggesting
Cocconi, 1999CMF, cisplatin, etoposide, and doxorubicinCMFsuggesting
Cocconi G, 1996MPEPIV or MPEMiCMFsuggesting
Kolaric, 1985CAPCMFVPsuggesting
Eisen, 1998EcisFECycloFnegative
Nielsen, 2000EPI + CISEPIsuggesting
Kolaric, 1989CAPFACsuggesting
Berruti A, 2002cisplatin + epirubicinlonidamine + epirubicinnegative
Berruti B, 2002cisplatin + epirubicinlonidamine + epirubicinsuggesting
Icli, 2002VP-16+Ppaclitaxelsuggesting
Fountzilas, 2002PCbPEnegative

FGFR inhibitors

not classified
NCT01528345 ongoing Dovitinib + Fulvestrantplacebo + Fulvestrant HT failure NCT01528345 ongoing

Gemcitabine containg regimen

gemcitabine
Seidman, 2011gemcitabine + docetaxel capecitabine + docetaxel -
Chan, 2009gemcitabine + docetaxelcapecitabine plus docetaxel -
Nielsen, 2011gemcitabine + docetaxeldocetaxel -
Feher, 2005gemcitabineepirubicin -
Brufsky, 2011gemcitabine + paclitaxel + bevacizumabpaclitaxel + bevacizumab -
Albain, 2008gemcitabine + paclitaxelpaclitaxel monotherapy -
Martín, 2007gemcitabine + vinorelbinevinorelbine monotherapy -
Papadimitriou, 2009gemcitabine + weekly docetaxelweekly docetaxel -

HER2 inhibitors

not classified
MO27775 ongoing pertuzumab + trastuzumab + aromatase inhibitortrastuzumab + aromatase inhibitor HER-2 positive HR positive NCT01491737 ongoing
PHEREXA ongoing pertuzumab + trastuzumab + capecitabinetrastuzumab + capecitabineNCT01026142 ongoing
SOPHIA ongoing margetuximabtrastuzumab + chemotherapy 2nd line 3rd line HER-2 positive previously treated by HER-2 antibody NCT02492711 ongoing
APHINITY (BIG 04-11) ongoing pertuzumab + trastuzumab + chemotherapytrastuzumab + chemotherapy HER-2 positive NCT01358877 ongoing
pertuzumab
CLEOPATRA, 2012pertuzumab + trastuzumab +docetaxeltrastuzumab + docetaxel 1st line HER-2 positive NCT00567190Low risk of bias suggesting
neoSphere (Group B), 2012pertuzumab + trastuzumab +docetaxeltrastuzumab + docetaxel HER-2 positive NCT00545688Exploratory -
trastuzumab
TAnDEM (Kaufman), 2009trastuzumab + anastrozoleanastrozole alone HER-2 positive HR positive -
von Minckwitz, 2009trastuzumab + capecitabinecapecitabine alone HER-2 positive previously treated by HER-2 antibody trastuzumab failure -
Marty, 2005trastuzumab + docetaxeldocetaxel alone 1st line HER-2 positive M77001 -
Blackwell, 2010trastuzumab + lapatiniblapatinib alone ErbB2 positive previously treated by HER-2 antibody trastuzumab failure -
Huober, 2012trastuzumab + letrozoleletrozole alone HER-2 positive HR positive -
Gasparini, 2006trastuzumab + paclitaxelpaclitaxel alone HER-2 positive -
Slamon, 2001trastuzumab + standard chemotherapystandard chemotherapy alone HER-2 positive -
trastuzumab emtansine
EMILIA, 2012trastuzumab emtansinelapatinib plus capecitabine 2nd line HER-2 positive previously treated by HER-2 antibody previously treated by taxanes NCT00829166suggesting
TH3RESA, 2014trastuzumab emtansineusual care 2nd+ line HER-2 positive previously treated by HER-2 antibody NCT01419197Risk of bias suggesting

high dose chemotherapy

not classified
ECOG, 200high-dose chemotherapyconventional-dose chemotherapynegative
IBDIS, 2003high-dose chemotherapyconventional-dose chemotherapynegative
NCIC, 2001high-dose chemotherapyconventional-dose chemotherapynegative
PEGASE 03, 2002high-dose chemotherapyconventional-dose chemotherapynegative
PEGASE 04, 1999high-dose chemotherapyconventional-dose chemotherapynegative
Schmid, 2005high-dose chemotherapyconventional-dose chemotherapynegative

histone deacetylase (HDAC) inhibitors

entinostat
ENCORE 301, 2013Entinostat + exemestaneexemestaneNCT00676663 -
NCT02115282 ongoing Entinostat + exemestaneexemestaneNCT02115282 ongoing
NCT02115594 ongoing Entinostat + fulvestrantfulvestrantNCT02115594 ongoing

immune checkpoint inhibition

not classified
NCT02614833 ongoing IMP321placeboNCT02614833 ongoing

ixabepilone based chemotherapy

ixabepilone
Sparano, 2010ixabepilone (on top capecitabine)no ixabepiloneRisk of bias negative
Thomas, 2007ixabepilone (on top capecitabine)no ixabepiloneRisk of bias suggesting

locoregional treatment of the primary tumor

not classified
Badwe, 2015locoregional treatmentno treatment of the primary tumour -

maintenance chemotherapy

not classified
Mayordomo, 2009negative
Harris, 1990maintenancecontrolnegative
Muss, 1991maintenancecontrolnegative
Gregory, 1997maintenancecontrolnegative
Falkson, 1998maintenancecontrolnegative
Nooij, 2003maintenancecontrolnegative
Gennari, 2006maintenancecontrolnegative
Alba, 2010maintenancecontrolnegative
Coates, 1987continuousintermittentnegative
Ejlertsen, 1993longshortsuggesting
French Epirubicin Study Group, 2000longshortnegative

mTOR inhibitor

not classified
MAIN-A ongoing maintenance everolimus + AIAI alone HER-2 positive HR positive maintenance therapy NCT02511639 ongoing
BOLERO-6 (combination) ongoing everolimus + exemestanecapecitabine HER-2 negative HR positive nsNAI failure postmenopausal previously treated with endocrine therapy NCT01783444Exploratory ongoing
BOLERO-4 ongoing everolimus + letrozoleletrozole alone 1st line HER-2 negative HR positive postmenopausal NCT01698918Exploratory ongoing
BOLERO-1 ongoing everolimus + trastuzumab + paclitaxeltrastuzumab + paclitaxel HER-2 positive trastuzumab-naif NCT00876395 ongoing
everolimus
BOLERO-2, 2011everolimus + exemestaneexemestane alone HER-2 negative HR positive nsNAI failure previously treated with endocrine therapy NCT00863655Low risk of bias conclusive
TAMRAD , 2012everolimus + tamoxifentamoxifen alone 1st line HER-2 negative HR positive postmenopausal previously treated with endocrine therapy NCT01298713Exploratory suggesting
BOLERO-3, 2014everolimus + trastuzumab + vinorelbinetrastuzumab + vinorelbine alone HER-2 positive previously treated by taxanes trastuzumab failure NCT01007942Low risk of bias conclusive
temsirolimus
HORIZON, 2013temsirolimus + letrozoleletrozole alone 1st line HR positive postmenopausal NCT00083993Low risk of bias negative

multi target TKI

not classified
Geyer, 2006lapatinib + capecitabinecapecitabine alone 2nd line HER-2 positive previously treated by HER-2 antibody previously treated by taxanes NCT00078572Risk of bias suggesting
100151 ongoing lapatinib + capecitabinecapecitabine alonemetastatic NCT00078572 ongoing
NCI-2009-00475 ongoing lapatinib + fulvestrantfulvestrant alonemetastaticNCT00390455 ongoing
CDR0000596572 ongoing lapatinib + fulvestrantfulvestrant alonemetastaticNCT00688194 ongoing
NALA ongoing neratinib + capecitabinelapatinib + capecitabineNCT01808573 ongoing
NCT01528345 ongoing Dovitinib + Fulvestrantplacebo + Fulvestrant HT failure NCT01528345 ongoing
DETECT III ongoing lapatinib + standard therapystandard therapy alonemetastatic NCT01619111 ongoing
NCT01160211 ongoing lapatinib + trastuzumab + aromatase inhibitortrastuzmab +aromatase inhibitormetastaticNCT01160211 ongoing
111438 ongoing lapatinib + capecitabinetrastuzumab + capecitabinemetastatic NCT00820222 ongoing
1200.75 ongoing BIBW 2992 + vinorelbinetrastuzumab + vinorelbinemetastatic NCT01125566 ongoing
112515 ongoing lapatinib + trastuzumabtrastuzumab alonemetastatic NCT00968968 ongoing
lapatinib
Johnston (EGF30008) , 2009lapatinib + letrozoleletrozole alone HR positive NCT00073528Low risk of bias conclusive
Di Leo, 2008lapatinib + paclitaxelpaclitaxel alone 1st line NCT00075270Low risk of bias negative
paclitaxel
ICORG 11-10 ongoing lapatinib + paclitaxel + trastuzumabpaclitaxel + trastuzumabmetastatic NCT01526369 ongoing
EGF104535 ongoing lapatinib + paclitaxelpaclitaxel alonemetastaticNCT00281658 ongoing
sorafenib
Baselga, 2012sorafenib + capecitabinecapecitabine alone HER-2 negative Exploratory suggesting
RESILIENCE, 2013 ongoing sorafenib + capecitabinecapecitabine alone ongoing
Schwartzberg, 2013sorafenib + gemcitabine or capecitabinegemcitabine or capecitabine alone 2nd line HER-2 negative NCT00493636Exploratory suggesting
Gradishar, 2013sorafenib + paclitaxelpaclitaxel alone 1st line HER-2 negative Exploratory negative

nontaxane microtubule dynamics inhibitor

eribulin
Trial 301 (Kaufman), 2015eribulincapecitabineNCT00337103Risk of bias negative
SCRI BRE 197 ongoing eribulin+cyclophosphamidedocetaxel+cyclophosphamideNCT01527487 ongoing
Vahdat, 2013eribulinixabepiloneNCT00879086Exploratory -
NCT02037529 ongoing eribulinpaclitaxelNCT02037529Risk of bias ongoing
2014-0857 ongoing eribulin+gemcitabinepaclitaxel+gemcitabineNCT02263495Exploratory ongoing
EMBRACE (Cortes), 2011eribulintreatment of physicianNCT00388726Risk of bias conclusive
E7389-C086-304 ongoing eribulinvinorelbineNCT02225470Exploratory ongoing

Phosphoinositide 3-kinase inhibitor

not classified
B-YOND ongoing BYL719 + TAM + GosBKM120 + TAM + GosNCT02058381 ongoing
SOLAR-1 ongoing alpelisib + fulvestrantfulvestrant aloneNCT02437318 ongoing
BELLE-2 ongoing BKM120 + fulvestrantfulvestrant alone 2nd line NCT01610284 ongoing
BELLE-3 ongoing BKM120 + fulvestrantfulvestrant alone 2nd line NCT01633060 ongoing
NCT01437566 ongoing GDC0941/GDC0980fulvestrant alone 2nd line NCT01437566 ongoing
GO29058 ongoing taselisib + fulvestrantfulvestrant aloneNCT02340221 ongoing
BELLE-4 ongoing BKM120 + paclitaxelpaclitaxel 1st line NCT01572727 ongoing
NCT01082068 ongoing XL147 (SAR245408) + letrozoleXL765 + letrozole 2nd line NCT01082068 ongoing

poly ADP-ribose polymerase (PARP) inhibitor

niraparib
BRAVO ongoing niraparibPhysician s choice chemotherapy BRCA-mutated NCT01905592 ongoing
olaparib
OlympiAD, 2017olaparibPhysician s choice chemotherapy BRCA-mutated HER-2 negative NCT02000622Risk of bias conclusive
talazoparib
EMBRACA ongoing talazoparibPhysician s choice chemotherapy BRCA-mutated NCT01945775 ongoing
veliparib
NCT02163694 ongoing veliparib with carboplatin and caclitaxelPlacebo with Carboplatin and Paclitaxel BRCA-mutated HER-2 negative NCT02163694 ongoing

Selective estrogen receptor downregulators (SERDs)

fulvestrant
GEICAM/2006-10fulvestrant + anastrozoleanastrozole HER-2 negative HR positive postmenopausal NCT00543127 -
FACT (Bergh), 2012fulvestrant + anastrozoleanastrozole first line of endocrine therapy HR positive postmenopausal NCT00256698negative
Mehta(SWOG-S0226), 2012fulvestrant + anastrozoleanastrozole HR positive NCT00075764suggesting
CDR0000349337 ongoing fulvestrant + anastrozoleanastrozole first line of endocrine therapy postmenopausal NCT00075764 ongoing
Xu et al., 2011fulvestrant 250mganastrozole HR positive postmenopausal NCT00327769 -
0021 (Osborne), 2002fulvestrant 250mganastrozole postmenopausal NCT00635713negative
0020 (Howell), 2002fulvestrant 250mganastrozolenegative
A011106 ongoing fulvestrant 250mganastrozoleNCT01953588 ongoing
FIRST (Robertson), 2010fulvestrant 500mganastrozole first line of endocrine therapy postmenopausal NCT00274469suggesting
FALCON ongoing fulvestrant 500mganastrozole first line of endocrine therapy NCT01602380 ongoing
FUMANCE ongoing fulvestrant 500mgcontrol maintenance therapy postmenopausal NCT02383030 ongoing
9238UK/0005 (fluvestrant alone)fluvestrant 250mgexemestane postmenopausal previously treated with endocrine therapy NCT00944918 -
SoFEa (Johnston) fluvestrant alone, 2012fluvestrant 250mgexemestane postmenopausal previously treated with endocrine therapy NCT00253422 -
9238UK/0005 (combination)fulvestrant + anastrozoleexemestane postmenopausal previously treated with endocrine therapy NCT00944918 -
SoFEa (Johnston) combination, 2012fulvestrant + anastrozoleexemestane HR positive postmenopausal previously treated with endocrine therapy NCT00253422negative
EFECT (Chia)fulvestrant 250mgexemestane HR positive postmenopausal NCT00065325negative
D6997L00021fulvestrant 500mgfulvestrant 250mg HR positive previously treated with endocrine therapy NCT01300351 -
CONFIRM (Di Leo), 2010fulvestrant 500mgfulvestrant 250mg HR positive previously treated with endocrine therapy NCT00099437 -
FINDER 1 (Ohno), 2010fulvestrant 500mgfulvestrant 250mg postmenopausal -
FINDER 2, 2010fulvestrant 500mgfulvestrant 250mg postmenopausal previously treated with endocrine therapy NCT00313170Exploratory -
9238IL/0025fulvestrant 250mgtamoxifen first line of endocrine therapy NCT00241449 -
0025 (Howell), 2004fulvestrant 250mgtamoxifen previously treated with endocrine therapy negative

Taxanes

not classified
NabholtzExploratory suggesting
Yardley, 2009Exploratory negative
AGO, 1998Exploratory negative
LymanExploratory suggesting
TRAVIOTAExploratory negative
EU-1, 2004Exploratory suggesting
306 Study Group, 2003docetaxel + doxorubicindoxorobicin + cyclophosphamide 1st line Risk of bias suggesting
EORTC 10961, 2002paclitaxel + doxorubicindoxorobicin + cyclophosphamide 1st line Exploratory negative
303 Study Group, 1999docetaxeldoxorubicin 2nd+ line Risk of bias suggesting
tnAcity ongoing nab-paclitaxel + gemcitabine or carboplatingemcitabine or carboplatinNCT01881230 ongoing
Meier, 2008docetaxelvinorelbine 2nd+ line previous anthracycline Exploratory negative
docetaxel
JCOG, 2005docetaxeldoxorubicin + cyclophosphamide 1st line Exploratory negative
Blohmer, 2010docetaxel + epirubicinepirubicin, cyclophosphamide 1st line Risk of bias negative
Rivera , 2008Weekly DocetaxelEvery three weeks Docetaxel -
Tabernero , 2004Weekly DocetaxelEvery three weeks Docetaxel -
Sedky , 2002Weekly DocetaxelEvery three weeks Docetaxel -
Willemse , 2007Weekly DocetaxelEvery three weeks Docetaxel -
Bontenbal, 2005docetaxel + doxorubicinfluorouracil, doxorubicin, cyclophosphamide 1st line Risk of bias suggesting
Bonneterre, 2004docetaxel + epirubicinfluorouracil, epirubicin, cyclophosphamideRisk of bias suggesting
TXT Group, 2002docetaxelfluorouracil, vinorelbine 2nd line previous anthracycline Exploratory suggesting
304 Study Group, 1999docetaxelmitomycin, vinblastine 2nd+ line previous anthracycline Risk of bias suggesting
Sjostrom, 1999docetaxelsequential methotrexate and 5-fluorouracil 2nd+ line previous anthracycline Exploratory suggesting
HERNATA, 2011docetaxel + trastuzumabvinorelbine, trastuzumab 1st line HER-2 positive Exploratory suggesting
nab-paclitaxel
Gradishar, 2009nab-paclitaxeldocetaxel 1st line NCT00274456Exploratory -
Roy, 2008nab-paclitaxel +gencotabinegencitabine 1st line NCT00110084 -
paclitaxel
Talbot, 2002pacclitaxelcapecitabineExploratory negative
TOG, 2005paclitaxelcisplatin, etoposideExploratory negative
ANZ TITG, 1999paclitaxelCMFP 1st line Risk of bias suggesting
ECOG E1193 (B), 2003paclitaxeldoxorubicinExploratory negative
EORTC 10923, 2000paclitaxeldoxorubicin 1st line Exploratory negative
UKCCCR AB01, 1997paclitaxel + epirubicinepirubicin, cyclophosphamide 1st line Exploratory suggesting
Gradishar , 2009Weekly PaclitaxelEvery three weeks DocetaxelExploratory negative
Fountzilas , 2008Weekly PaclitaxelEvery three weeks Docetaxelnegative
Khoo , 2006split doseEvery three weeks Paclitaxel not previously treated by anthracycline negative
CLGB 9840 (Seidman), 2008Weekly PaclitaxelEvery three weeks Paclitaxelsuggesting
Frasci , 2006Weekly PaclitaxelEvery three weeks Paclitaxelnegative
Frasci , 2005Weekly PaclitaxelEvery three weeks Paclitaxelnegative
Sikov , 2002Weekly PaclitaxelEvery three weeks Paclitaxelnegative
Jassem, 2001paclitaxel + doxorubicinfluorouracil, doxorubicin, cyclophosphamide 1st line Exploratory suggesting
CECOG BM1, 2005gemcitabine, epirubicin, paclitaxelfluorouracil, epirubicin, cyclophosphamide 1st line Exploratory suggesting
Dieras, 1995paclitaxelmitomycinExploratory negative

Vinorelbine containing regimen

vinorelbine
Meier, 2008 -
Martin, 2007 -
Kim, 2006 -
Norris, 2000 -